PaySign, Inc. Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $21.6 million, a 41.6% increase year-over-year.

Adjusted EBITDA: $5 million, up 78% from the previous year.

Net Income: $2.2 million, or $0.04 per fully diluted share, a 54% increase from $1.4 million, or $0.03 per share, in Q3 2024.

Patient Affordability Revenue: $7.9 million, a 142% increase, representing 36.7% of total revenue.

Plasma Revenue: $12.9 million, a 12.4% increase year-over-year.

Gross Profit Margin: Improved to 56.3%, up 72 basis points.

Operating Expenses: Improved to 48.9% of revenue, with SG&A expenses down to 32.9% of revenue.

2Strategic Updates and Business Highlights

Patient Affordability Growth: The business segment continues to expand, with 105 active programs and plans to reach 125-135 by year-end.

New Patient Support Center: A new 30,000 square foot facility was opened, quadrupling support capacity and enhancing service delivery.

Dynamic Business Rules Technology: This proprietary technology is being integrated into pharmacy claims processes, driving significant savings for clients.

Plasma Business: Despite a net loss of 12 centers, the average donor compensation increased, and the company anticipates normalization of plasma supply issues by 2026.

Software as a Service (SaaS) Platform: The company is awaiting FDA clearance for its blood establishment computer system (BECCS), which is generating strong interest in the market.

3Forward Guidance and Outlook

Revenue Guidance: Raised to $80.5 million to $81.5 million for 2025, reflecting a year-over-year growth of approximately 38.7%.

Net Income Estimates: Revised to between $7 million and $8 million, or $0.12 to $0.13 per diluted share.

Adjusted EBITDA Guidance: Expected to be in the range of $19 million to $20 million, or $0.32 to $0.34 per diluted share.

Gross Profit Margin: Expected to be around 60% for the full year.

4Bad News, Challenges, or Points of Concern

Plasma Business Headwinds: The plasma industry is experiencing an oversupply, which is expected to normalize in 2026. This has impacted revenue per plasma center, which declined to $7,122.

Operational Challenges: New plasma centers are not yet fully mature, affecting margins. The company is investing in infrastructure and personnel, leading to increased operating expenses.

Regulatory Delays: The FDA clearance for the BECCS may be delayed due to external factors, impacting the timeline for revenue generation from this new business line.

5Notable Q&A Insights

Pipeline Mix: The company indicated a shift towards more retail programs, which typically have higher patient counts and claims volumes compared to specialty drugs.

Gross Profit Margin Expectations: As new centers mature and the patient support center ramps up, gross profit margins are expected to improve.

Donor Dynamics: No significant changes in donor behavior were noted in relation to government shutdowns or immigration policies, with expectations for donor payments to increase in the coming months.

Program Revenue Variability: The revenue generated from mature programs varies significantly, making it difficult to predict exact figures. The focus remains on year-over-year comparisons rather than sequential metrics. Overall, PaySign reported a strong quarter with significant growth in revenue and EBITDA, while also navigating challenges in the plasma business and awaiting regulatory approvals for new technology offerings. The outlook remains positive, with raised guidance reflecting confidence in continued growth.